| |
|
A WEEK-IN-REVIEW FEATURED REPORT
Distinct resistance patterns to etravirine and rilpivirine in
viruses containing nnrti mutations at baseline.
Asahchop EL, Wainberg MA, Oliveira M,
et al
AIDS.
2012 Dec 19.
Abstract
A WEEK-IN-REVIEW FEATURED ARTICLE
Preexisting mutations in the rilpivirine Phase III trials ECHO
and THRIVE: prevalence and impact on virologic response.
Vingerhoets J, Rimsky L, Van Eygen V,
et al
Antivir Ther.
2012 Sep 6.
Abstract
FULL-TEXT PDF ARTICLE
Biochemical Mechanism of HIV-1 Resistance to Rilpivirine.
Singh K, Marchand B, Rai DK, et al
J Biol Chem.
2012 Sep 6
Paper
Rilpivirine Resistance Mutations in HIV Patients Failing
Non-Nucleoside Reverse Transcriptase Inhibitor-Based Therapies.
Anta L, Llibre JM,
Poveda E, et al
AIDS.
2012 Aug 7.
Abstract |
FULL-TEXT ARTICLE
Panel of
prototypical recombinant infectious molecular clones resistant to nevirapine,
efavirenz, etravirine, and rilpivirine.
Balamane M, Varghese V, Melikian GL,
et al
Antimicrob Agents Chemother.
2012 Aug;56(8):4522-4
Paper
|
Minority variants associated with resistance to HIV-1
nonnucleoside reverse transcriptase inhibitors during
primary infection.
Nicot F, Saliou A,
Raymond S, et al
J
Clin Virol. 2012 Jul 19.
Abstract |
E138K and M184I mutations in HIV-1 reverse transcriptase co-emerge as a result
of APOBEC3 editing in the
absence of drug exposure.
Fourati S, Malet I,
Lambert S, et al
AIDS.
2012 Jun 12
Abstract
A WEEK-IN REVIEW FEATURED REPORT
Panel of Prototypical Recombinant Infectious Molecular Clones
Resistant to Nevirapine, Efavirenz,
Etravirine, and Rilpivirine.
Balamane M, Varghese V, Melikian GL, et al
Antimicrob Agents Chemother.
2012 Jun 4.
Abstract |
A WEEK-IN REVIEW FEATURED REPORT
Prevalence of TMC278 (rilpivirine) associated mutations
in the Frankfurt Resistance Database.
Reinheimer C, Doerr HW, Stürmer M. et al
J Clin Virol.
2011 Dec 30.
Abstract |
| |
|
| |
Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults
failing non-nucleoside
reverse transcriptase inhibitor-based regimens.
Bunupuradah T, Ananworanich J,
Chetchotisakd P,
et al
Antivir Ther.
2011;16(7):1113-21
Abstract |
| |
A WEEK-IN-REVIEW FEATURED ARTICLE
Where rilpivirine meets with tenofovir, the start of a
new anti-HIV drug combination era.
De Clercq E.
Biochem Pharmacol.
2012 Apr 5.
Abstract
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients
with hepatitis B virus/hepatitis C virus
coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE
trials.
Nelson M, Amaya G,
Clumeck N,
et al
J Antimicrob Chemother. 2012 Apr 24.
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48
weeks in treatment-naďve,
HIV-1-infected
patients: Pooled results from the phase 3 double-blind,
randomized ECHO and THRIVE trials.
Cohen C, Molina J, Cahn P, et al
J Acquir Immune Defic Syndr.
2012 Feb 16
Abstract |
| |
|
| |
Rilpivirine versus efavirenz with tenofovir and emtricitabine in
treatment-naive adults infected with HIV-1 (ECHO):
a phase 3 randomised
double-blind active-controlled trial.
Molina JM, Cahn P, Grinsztejn
B. et al
Lancet.
2011 Jul
16;378(9787):238-46.
Abstract |
| |
|
| |
Rilpivirine versus efavirenz with two background nucleoside or nucleotide
reverse transcriptase inhibitors
in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised,
non-inferiority trial.
Cohen CJ, Andrade-Villanueva J, Clotet B,
et al
Lancet. 2011 Jul 16;378(9787):229-37.
Abstract
|
| |
New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics,
and resistance profile
of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.
Hughes CA, Robinson L, Tseng A, Macarthur RD.
Expert Opin Pharmacother. 2009
Aug 13.
Abstract |
|
General
Reports
Rilpivirine Main Page